Nomura Securities Starts Akebia Therapeutics (AKBA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Akebia Therapeutics (AKBA) Surges as Wall Street Screams 'Buy'
April 14, 2014 3:39 PM EDTAkebia Therapeutics (NASDAQ: AKBA) is zooming higher in mid-day trade as momentum traders jump on the name amid positive analysts coverage and aggressive prices targets from four Wall Street firms... More
UPDATE: UBS Starts Akebia Therapeutics (AKBA) at Buy
April 14, 2014 8:14 AM EDT(Updated - April 14, 2014 1:37 PM EDT)
UBS initiated coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target of $28.00.
Analyst Matthew Roden said, "Key tenets of our Buy thesis: [1] HIF... More
Credit Suisse Starts Akebia Therapeutics (AKBA) at Outperform
April 14, 2014 8:14 AM EDTCredit Suisse initiated coverage on Akebia Therapeutics (NASDAQ: AKBA) with an Outperform rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Akebia Therapeutics click here. For more ratings news on Akebia Therapeutics click here.
Shares of Akebia Therapeutics closed at $16.86 yesterday.
... MoreMorgan Stanley Starts Akebia Therapeutics (AKBA) at Overweight w/PT of $90
April 14, 2014 8:13 AM EDTMorgan Stanley initiated coverage on Akebia Therapeutics (NASDAQ: AKBA) with an Overweight rating and a price target of $90.
Analyst David Friedman said "We see Akebias lead asset, AKB-6548, as having $2+bn... More
